ArticleFrontiers in oncology2026
The ATM inhibitor KU55933 inhibits TGF-β1-mediated epithelial to mesenchymal transition in colorectal cancer cells.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC) remains a major cause of cancer death worldwide, largely due to metastasis and drug resistance. The epithelial-mesenchymal transition (EMT) is known to drive CRC metastasis. ATM kinase has been reported to influence the Akt signaling pathway, which itself plays a central role in EMT. Methods: We examined whether the ATM inhibitor KU55933 could interfere with TGF-β1-induced EMT in two human CRC cell lines, SW620 and HT29. Cells were exposed to TGF-β1 with or without KU55933 (or KU60019). EMT was assessed by cell morphology and Western blotting for epithelial and mesenchymal markers. Migration was measured by wound healing assay, and invasion by Matrigel assay. Apoptosis and proliferation were evaluated by flow cytometry and MTT assay. To explore the underlying mechanism, we analyzed Akt pathway signaling by Western blot and performed KEGG pathway enrichment on gene expression changes. A xenograft model was also used to test the Results: KU55933 effectively reversed the morphological changes triggered by TGF-β1. It reduced mesenchymal markers Vimentin and N-cadherin while upregulating the epithelial marker E-cadherin. At the mechanistic level, KU55933 was associated with reduced phospho-AKT Ser473 and phospho-GSK-3β Ser9 signals, together with lower expression of the transcription factors ZEB1, Snail, and Twist-1. KEGG pathway analysis showed that differentially expressed genes between the TGF-β1 and TGF-β1 plus KU55933 groups were significantly enriched in the PI3K-Akt signaling pathway. Functionally, the inhibitor significantly suppressed TGF-β1-driven migration and invasion and promoted apoptosis. Conclusion: Our data indicate that KU55933 and KU60019 attenuate TGF-β1-induced EMT-associated phenotypes, migration, and invasion in CRC cells, accompanied by reduced AKT-related signaling, while also promoting apoptosis and suppressing xenograft growth. These findings support further investigation of pharmacological ATM inhibition as a potential strategy for limiting CRC progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.